SCHEMBL716170

SCHEMBL716170

Cc1cccc2cc(CO)c(N3CCOCC3)nc12

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 9/20 0.58
PIK3C2B O00750 2/20 0.51
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
USP2 O75604 1/20 0.45
CLK1 P49759 1/20 0.45
OPRK1 P41145 1/20 0.44
PIK3CG P48736 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718208 0.88 L3MBTL1 (0.60) PIK3CDKDM4EMEN1KMT2ATSHR
SCHEMBL15864240 0.88 PIK3CD (0.54) PIK3CDPIK3C2BKDM4EMEN1KMT2A
SCHEMBL15864430 0.83 PIK3CD (0.56) PIK3CDPIK3C2BKDM4EMEN1KMT2A
SCHEMBL15875824 0.81 L3MBTL1 (0.53) PIK3CDKDM4ETSHRALOX15CASP1
SCHEMBL15870161 0.78 PIK3CD (0.47) PIK3CDPIK3C2BKDM4EMEN1KMT2A
SCHEMBL14838650 0.77 KDM4E (0.61) PIK3CDKDM4EMEN1KMT2ATSHR
SCHEMBL713514 0.76 PIK3CD (0.48) PIK3CDKDM4ETSHRALOX15CASP1
SCHEMBL714331 0.76 PIK3CD (0.59) PIK3CDPIK3C2BKDM4EMEN1KMT2A
SCHEMBL15870051 0.76 PIK3CD (0.49) PIK3CDPIK3C2BKDM4EMEN1KMT2A
SCHEMBL15864428 0.76 PIK3CD (0.47) PIK3CDPIK3C2BKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885PIK3C2B 69/4885KDM4E 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.